Personalized mRNA vaccine for advanced digestive cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized mRNA vaccine designed to target unique markers on your cancer cells. The vaccine is made just for you based on genetic testing of your tumor. It is for people with advanced digestive system cancers who have run out of standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced (spread or cannot be removed) cancer of the digestive system, such as stomach, colon, pancreas, or liver.
- Standard treatments must have stopped working, or you couldn't take them due to side effects, or you chose not to take them.
- You need to be between 18 and 75 years old and your doctor expects you to live at least 6 more months.
- You must have tumor tissue available for genetic analysis (either a fresh sample or previous test results).
- Your overall health and organ function (heart, liver, kidneys, blood counts) must be within study limits—your study doctor will check this.
- You cannot have serious infections (like tuberculosis, hepatitis B/C, HIV), untreated brain metastases, or certain heart or lung diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) given alongside standard first-line treatment for advanced digestive system cancers. The vaccine is made specifically for your tumor's unique genetic changes (neoantigens) and aims to help your immune system fight the cancer more effectively.
This trial tests a personalized mRNA vaccine designed to train your immune system to fight your specific cancer. It's for people who have just had surgery to remove a digestive system cancer (like pancreatic or colorectal) and will also receive standard chemotherapy after surgery.
This trial tests a personalized mRNA vaccine designed to teach your immune system to attack your specific tumor. It is for people with advanced gastrointestinal cancers who have exhausted other options.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a personalized mRNA vaccine made from your own tumor's unique markers (neoantigens). It is for people with advanced pancreatic cancer that has spread or come back, and who have had limited or no prior chemotherapy. The goal is to see if this vaccine can help the immune system fight the cancer.
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It's for people with advanced bile duct cancer that hasn't been treated yet, to see if it can help their immune system fight the cancer.
Hear when a new Digestive System Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.